Biomarkers & Translational Tools

Member Services Networks and Communities Translational & Precision Medicine Biomarkers & Translational Tools

Biomarkers and Translational Tools (BTT) Community

Description & Goals

Mission Statement:

The Biomarkers & Translational Tools (BTT) Community seeks to promote the use and advancement of biomarkers and other translational tools for optimization of drug development and patient care through the dissemination of knowledge and engagement of BTT members.

Vision Statement:

BTT envisions a Community of biomarker leaders and enthusiasts at all career stages whom the clinical pharmacology and translational science field turns to for expertise and support.

Rhythm of Business

Monthly leaders’ and steering committee meetings.
Weekly social media communications on recent developments relevant to the field.
Educational and networking opportunities via periodic webinars, Annual Meeting activities, and position papers.

For More Information on Getting Involved:

Join the BTT LinkedIn group: https://www.linkedin.com/groups/8630604/
Contact: Mai.Mehanna@fda.hhs.gov

Community Connection

Join the LinkedIn Group.

Past Webinars

The webinars below can be accessed in the Members Only Webinar Library: Access Library

We Are All Patients
The Application of Model-Informed Drug Development in Rare Disease Development
Fit-for-Purpose Biometric Monitoring Technologies: Leveraging the Laboratory Biomarker Experience (open access)
Big Data in Immunology and Clinical Research: Sharing, Dissemination, and Repurposing
Taking A Second Look: A Type 2 Diabetes Subtype Responsive to Intensive Glycemia Treatment in the ACCORD Trial
Clinical Trials in the Pediatric CKD Population: Challenges and Opportunities
Drug Re-purposing Opportunities Using Shared Gene Expression Molecular Signatures - Case Studies in Neurodegenerative Diseases and Infections
Biomarkers and Experimental Human Models in Clinical Development and Practice
Quantitative Systems Pharmacology (QSP) Modeling of Drug-Induced Nephrotoxicity – Bridging the Link Between Drug Exposure, Urinary Biomarkers and Renal Dysfunction
Clinical Outcome After Therapy for MDD